Skip to main content
Erschienen in: Medical Oncology 3/2013

01.09.2013 | Review Article

Identifying oncological emergencies

verfasst von: Achuta K. Guddati, Nilay Kumar, Ankur Segon, Parijat S. Joy, Creticus P. Marak, Gagan Kumar

Erschienen in: Medical Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Prompt identification and treatment of life-threatening oncological conditions is of utmost importance and should always be included in the differential diagnosis. Oncological emergencies can have a myriad of presentations ranging from mechanical obstruction due to tumor growth to metabolic conditions due to abnormal secretions from the tumor. Notably, hematologic and infectious conditions may complicate the presentation of oncological emergencies. Advanced testing and imaging is generally required to recognize these serious presentations of common malignancies. Early diagnosis and treatment of these conditions can significantly affect the patient’s clinical outcome.
Literatur
1.
Zurück zum Zitat Yim CD, Sane SS, Bjarnason H. Superior vena cava stenting. Radiol Clin North Am. 2000;38(2):409–24.CrossRefPubMed Yim CD, Sane SS, Bjarnason H. Superior vena cava stenting. Radiol Clin North Am. 2000;38(2):409–24.CrossRefPubMed
2.
Zurück zum Zitat Abrahm JL. Management of pain and spinal cord compression in patients with advanced cancer. ACP–ASIM End-of-life care consensus panel. American College of Physicians-American Society of Internal Medicine. Ann Intern Med. 1999;131(1):37–46.CrossRefPubMed Abrahm JL. Management of pain and spinal cord compression in patients with advanced cancer. ACP–ASIM End-of-life care consensus panel. American College of Physicians-American Society of Internal Medicine. Ann Intern Med. 1999;131(1):37–46.CrossRefPubMed
4.
Zurück zum Zitat Allen KB, Faber LP, Warren WH, Shaar CJ. Pericardial effusion: subxiphoid pericardiostomy versus percutaneous catheter drainage. Ann Thorac Surg. 1999;67(2):437–40.CrossRefPubMed Allen KB, Faber LP, Warren WH, Shaar CJ. Pericardial effusion: subxiphoid pericardiostomy versus percutaneous catheter drainage. Ann Thorac Surg. 1999;67(2):437–40.CrossRefPubMed
6.
Zurück zum Zitat Colman RW, Rubin RN. Disseminated intravascular coagulation due to malignancy. Semin Oncol. 1990;17(2):172–86.PubMed Colman RW, Rubin RN. Disseminated intravascular coagulation due to malignancy. Semin Oncol. 1990;17(2):172–86.PubMed
7.
Zurück zum Zitat Sarris AH, Kempin S, Berman E, Michaeli J, Little C, Andreeff M, et al. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood. 1992;79(5):1305–10.PubMed Sarris AH, Kempin S, Berman E, Michaeli J, Little C, Andreeff M, et al. High incidence of disseminated intravascular coagulation during remission induction of adult patients with acute lymphoblastic leukemia. Blood. 1992;79(5):1305–10.PubMed
8.
Zurück zum Zitat Bick RL. Disseminated intravascular coagulation current concepts of etiology, pathophysiology, diagnosis, and treatment. Hematol Oncol Clin North Am. 2003;17(1):149–76.CrossRefPubMed Bick RL. Disseminated intravascular coagulation current concepts of etiology, pathophysiology, diagnosis, and treatment. Hematol Oncol Clin North Am. 2003;17(1):149–76.CrossRefPubMed
9.
Zurück zum Zitat Falanga A, Consonni R, Marchetti M, Locatelli G, Garattini E, Passerini CG, et al. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood. 1998;92(1):143–51.PubMed Falanga A, Consonni R, Marchetti M, Locatelli G, Garattini E, Passerini CG, et al. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood. 1998;92(1):143–51.PubMed
10.
Zurück zum Zitat Coiffier B, Mounier N, Bologna S, Ferme C, Tilly H, Sonet A, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin’s lymphoma: results of the GRAAL1 (Groupe d’Etude des lymphomes de l’adulte trial on rasburicase activity in adult lymphoma) study. J Clin Oncol. 2003;21(23):4402–6. doi:10.1200/JCO.2003.04.115.CrossRefPubMed Coiffier B, Mounier N, Bologna S, Ferme C, Tilly H, Sonet A, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin’s lymphoma: results of the GRAAL1 (Groupe d’Etude des lymphomes de l’adulte trial on rasburicase activity in adult lymphoma) study. J Clin Oncol. 2003;21(23):4402–6. doi:10.​1200/​JCO.​2003.​04.​115.CrossRefPubMed
11.
Zurück zum Zitat Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis Off Publ Infect Dis Soc Am. 2011;52(4):427–31. doi:10.1093/cid/ciq147.CrossRef Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis Off Publ Infect Dis Soc Am. 2011;52(4):427–31. doi:10.​1093/​cid/​ciq147.CrossRef
12.
Zurück zum Zitat Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med. 1975;135(5):715–9.CrossRefPubMed Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med. 1975;135(5):715–9.CrossRefPubMed
13.
Zurück zum Zitat Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis Off Publ Infect Dis Soc Am. 2002;34(6):730–51. doi:10.1086/339215.CrossRef Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis Off Publ Infect Dis Soc Am. 2002;34(6):730–51. doi:10.​1086/​339215.CrossRef
14.
Zurück zum Zitat Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infectious diseases society of America. Clin Infect Dis Off Publ Infect Dis Soc Am. 2009;49(1):1–45. doi:10.1086/599376.CrossRef Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infectious diseases society of America. Clin Infect Dis Off Publ Infect Dis Soc Am. 2009;49(1):1–45. doi:10.​1086/​599376.CrossRef
15.
Zurück zum Zitat Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis Off Publ Infect Dis Soc Am. 2011;52(4):e56–93. doi:10.1093/cid/cir073.CrossRef Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis Off Publ Infect Dis Soc Am. 2011;52(4):e56–93. doi:10.​1093/​cid/​cir073.CrossRef
16.
Zurück zum Zitat Flynn PM, Van Hooser B, Gigliotti F. Atypical mycobacterial infections of Hickman catheter exit sites. Pediatr Infect Dis J. 1988;7(7):510–3.CrossRefPubMed Flynn PM, Van Hooser B, Gigliotti F. Atypical mycobacterial infections of Hickman catheter exit sites. Pediatr Infect Dis J. 1988;7(7):510–3.CrossRefPubMed
17.
Zurück zum Zitat Allen U, Smith CR, Prober CG. The value of skin biopsies in febrile, neutropenic, immunocompromised children. Am J Dis Child. 1986;140(5):459–61.PubMed Allen U, Smith CR, Prober CG. The value of skin biopsies in febrile, neutropenic, immunocompromised children. Am J Dis Child. 1986;140(5):459–61.PubMed
18.
Zurück zum Zitat Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038–51.PubMed Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038–51.PubMed
19.
Zurück zum Zitat Recommendations for preventing the spread of vancomycin resistance. Recommendations of the hospital infection control practices advisory committee (HICPAC). MMWR Recommendations and reports : morbidity and mortality weekly report recommendations and reports/Centers for Disease Control. 1995;44(RR-12):1–13. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the hospital infection control practices advisory committee (HICPAC). MMWR Recommendations and reports : morbidity and mortality weekly report recommendations and reports/Centers for Disease Control. 1995;44(RR-12):1–13.
20.
Zurück zum Zitat Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Off Publ Infect Dis Soc Am. 1992;14(6):1201–7.CrossRef Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Off Publ Infect Dis Soc Am. 1992;14(6):1201–7.CrossRef
Metadaten
Titel
Identifying oncological emergencies
verfasst von
Achuta K. Guddati
Nilay Kumar
Ankur Segon
Parijat S. Joy
Creticus P. Marak
Gagan Kumar
Publikationsdatum
01.09.2013
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 3/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0669-6

Weitere Artikel der Ausgabe 3/2013

Medical Oncology 3/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.